Microenvironmental regulation of cancer stem cell phenotypes

Current Stem Cell Research and Therapy

Volumn 7, Issue 3, 2012, Pages 197-216

  Quail, Daniela F ^a   Taylor, Meghan J ^a   Postovit, Lynne Marie ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Cancer; Microenvironment; NODAL; NOTCH; Oxygen; Plasticity; WNT

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; CD133 ANTIGEN; CD151 ANTIGEN; CD9 ANTIGEN; CELL PROTEIN; DISHEVELLED PROTEIN; ERYTHROPOIETIN; FRIZZLED PROTEIN; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERCELLULAR ADHESION MOLECULE 1; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; OXYGEN; PROTEIN NODAL; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; WNT PROTEIN;

CANCER GROWTH; CANCER MODEL; CANCER STEM CELL; CARCINOGENESIS; CELL FATE; CELL RENEWAL; DNA DAMAGE; DNA MODIFICATION; DNA SEQUENCE; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENE REGULATORY NETWORK; GENOMIC INSTABILITY; HUMAN; NONHUMAN; OXYGEN TENSION; PHENOTYPE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; STEM CELL NICHE; STOCHASTIC MODEL; TUMOR MICROENVIRONMENT;

BIOLOGICAL MARKERS; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MUTATION; NEOPLASTIC STEM CELLS; NODAL PROTEIN; OXYGEN; RECEPTORS, NOTCH; STEM CELL NICHE; TUMOR MICROENVIRONMENT; WNT PROTEINS;

EID: 84860279966     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488812799859838     Document Type: Review

References (274)

1. Comings DE. A general theory of carcinogenesis. Proc Natl AcadSci USA 1973; 70(12): 3324-8.
2. Berenblum I, Shubik P. An experimental study of the initiatingstate of carcinogenesis, and a re-examination of the somatic cellmutation theory of cancer. Br J Cancer 1949; 3(1): 109-18.
3. Sorsa M. Somatic mutation theory. J Toxicol Environ Health 1980;6(5-6): 977-82.
4. Soto AM, Sonnenschein C. The somatic mutation theory of cancer:growing problems with the paradigm? Bioessays 2004; 26(10):1097-107.
5. Virchow RLK. In: Hirschwald A, editor. Cellular Pathology. 1858.
6. Murphy JB, Rous P. The behaviour of chicken sarcoma implantedin the developing embryo. J Exp Med 1912; 15(2): 119-32.
7. Rous P. A transmissible avian neoplasm (Sarcoma of the commonfowl). J Exp Med 1910; 12(5): 696-705.
8. Maeda N, Fan H, Yoshikai Y. Oncogenesis by retroviruses: old andnew paradigms. Rev Med Virol 2008; 18(6): 387-405.
9. Martin GS. The road to Src. Oncogene 2004; 23(48): 7910-7.
10. Weinstein IB, Case K. The history of Cancer Research: introducingan AACR Centennial series. Cancer Res 2008; 68(17): 6861-2.
11. Yamagiwa K, Ichikawa K. Experimental study of the pathogenesisof carcinoma. CA Cancer J Clin 1977; 27(3): 174-81.
12. Luch A. Nature and nurture-lessons from chemical carcinogenesis. Nat Rev Cancer 2005; 5(2): 113-25.
13. Rapp F. Current knowledge of mechanisms of viral carcinogenesis. Crit Rev Toxicol 1984; 13(2): 197-204.
14. Ames BN, Lee FD, Durston WE. An improved bacterial test systemfor the detection and classification of mutagens and carcinogens. Proc Natl Acad Sci USA 1973; 70(3): 782-6.
15. Ames BN, Durston WE, Yamasaki E, Lee FD. Carcinogens aremutagens: a simple test system combining liver homogenates foractivation and bacteria for detection. Proc Natl Acad Sci USA1973; 70(8): 2281-5.
16. Ames BN. A combined bacterial and liver test system for detectionand classification of carcinogens as mutagens. Genetics 1974;78(1): 91-5.
17. Ames BN, Kammen HO, Yamasaki E. Hair dyes are mutagenic:identification of a variety of mutagenic ingredients. Proc Natl AcadSci USA 1975; 72(6): 2423-7.
18. Durston WE, Ames BN. A simple method for the detection ofmutagens in urine: studies with the carcinogen 2-acetylaminofluorene. Proc Natl Acad Sci USA 1974; 71(3): 737-41.
19. Kier LD, Yamasaki E, Ames BN. Detection of mutagenic activityin cigarette smoke condensates. Proc Natl Acad Sci USA 1974;71(10): 4159-63.
20. Ames BN, Shigenaga MK, Gold LS. DNA lesions, inducible DNArepair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect 1993; 101 Suppl 5: 35-44.
21. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets forcancer. Nat Rev Clin Oncol 2009; 6(10): 587-95.
22. Scholl C, Gilliland DG, Frohling S. Deregulation of signalingpathways in acute myeloid leukemia. Semin Oncol 2008; 35(4):336-45.
23. Ciampolillo A, De TC, Giorgino F. The IGF-I/IGF-I receptorpathway: Implications in the Pathophysiology of Thyroid Cancer. Curr Med Chem 2005; 12(24): 2881-91.
24. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressorand pro-metastatic factor in human cancer. Biochim Biophys Acta2007; 1775(1): 21-62.
25. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, BrooksMW, Weinberg RA. Creation of human tumour cells with definedgenetic elements. Nature 1999; 400(6743): 464-8.
26. zur HH. Papillomaviruses and cancer: from basic studies to clinicalapplication. Nat Rev Cancer 2002; 2(5): 342-50.
27. Dotto GP, Parada LF, Weinberg RA. Specific growth response ofras-transformed embryo fibroblasts to tumour promoters. Nature1985; 318(6045): 472-5.
28. Rosen JM, Jordan CT. The increasing complexity of the cancerstem cell paradigm. Science 2009; 324(5935): 1670-3.
29. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acutemyeloid leukaemia after transplantation into SCID mice. Nature1994; 367(6464): 645-8.
30. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours:accumulating evidence and unresolved questions. Nat Rev Cancer2008; 8(10): 755-68.
31. Bonnet D, Dick JE. Human acute myeloid leukemia is organized asa hierarchy that originates from a primitive hematopoietic cell. NatMed 1997; 3(7): 730-7.
32. Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. ProcNatl Acad Sci USA 2003; 100(7): 3983-8.
33. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancerstem cell in human brain tumors. Cancer Res 2003; 63(18): 5821-8.
34. Singh SK, Hawkins C, Clarke ID, et al. Identification of humanbrain tumour initiating cells. Nature 2004; 432(7015): 396-401.
35. Suva ML, Riggi N, Janiszewska M, Radovanovic I, et al. EZH2 isessential for glioblastoma cancer stem cell maintenance. CancerRes 2009; 69(24): 9211-8.
36. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanomacells. Nature 2008; 456(7222): 593-8.
37. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification andexpansion of human colon-cancer-initiating cells. Nature 2007;445(7123): 111-5.
38. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancercell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445(7123): 106-10.
39. Smalley MJ, Reis-Filho JS, Ashworth A. BRCA1 and stem cells:tumour typecasting. Nat Cell Biol 2008; 10(4): 377-9.
40. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cellswithin tumour stroma promote breast cancer metastasis. Nature2007; 449(7162): 557-63.
41. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymaltransition. J Clin Invest 2009; 119(6): 1420-8.
42. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymaltransition generates cells with properties of stem cells. Cell 2008;133(4): 704-15.
43. Schier AF. Nodal signaling in vertebrate development. Annu RevCell Dev Biol 2003; 19: 589-621.
44. Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonicand tumorigenic pathways converge via Nodal signaling: role inmelanoma aggressiveness. Nat Med 2006; 12(8): 925-32.
45. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Influence of themicroenvironment on melanoma cell fate determination and phenotype. Cancer Res 2006; 66(16): 7833-6.
46. Postovit LM, Margaryan NV, Seftor EA, et al. Human embryonicstem cell microenvironment suppresses the tumorigenic phenotypeof aggressive cancer cells. Proc Natl Acad Sci USA 2008; 105(11):4329-34.
47. Lawrence MG, Margaryan NV, Loessner D, et al. Reactivation ofembryonic nodal signaling is associated with tumor progressionand promotes the growth of prostate cancer cells. Prostate 2011.
48. Hsu YC, Pasolli HA, Fuchs E. Dynamics between stem cells, niche, and progeny in the hair follicle. Cell 2011; 144(1): 92-105.
49. Chan EF, Gat U, McNiff JM, Fuchs E. A common human skintumour is caused by activating mutations in beta-catenin. Nat Genet1999; 21(4): 410-3.
50. Merlos-Suarez A, Barriga FM, Jung P, et al. The Intestinal StemCell Signature Identifies Colorectal Cancer Stem Cells and PredictsDisease Relapse. Cell Stem Cell 2011; 8(5): 511-24.
51. Schatton T, Murphy GF, Frank NY, et al. Identification of cellsinitiating human melanomas. Nature 2008; 451(7176): 345-9.
52. Zhong Y, Guan K, Zhou C, et al. Cancer stem cells sustaining thegrowth of mouse melanoma are not rare. Cancer Lett 2009; 292(1):17-23.
53. Hong H, Takahashi K, Ichisaka T, et al. Suppression of inducedpluripotent stem cell generation by the p53-p21 pathway. Nature2009; 460(7259): 1132-5.
54. Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributesto tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 2002; 99(20): 12606-11.
55. McAllister JC, Zhan Q, Weishaupt C, Hsu MY, Murphy GF. Theembryonic morphogen, Nodal, is associated with channel-likestructures in human malignant melanoma xenografts. J CutanPathol 2010; 37 Suppl 1: 19-25.
56. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicryand tumour-cell plasticity: lessons from melanoma. Nat RevCancer 2003; 3(6): 411-21.
57. Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics invasculogenic mimicry and angiogenesis of inflammatory breastcancer xenograft. Cancer Res 2002; 62(2): 560-6.
58. Sood AK, Fletcher MS, Zahn CM, et al. The clinical significanceof tumor cell-lined vasculature in ovarian carcinoma: implicationsfor anti-vasculogenic therapy. Cancer Biol Ther 2002; 1(6): 661-4.
59. Sharma N, Seftor RE, Seftor EA, et al. Prostatic tumor cell plasticityinvolves cooperative interactions of distinct phenotypic subpopulations:role in vasculogenic mimicry. Prostate 2002; 50(3):189-201.
60. Passalidou E, Trivella M, Singh N, et al. Vascular phenotype inangiogenic and non-angiogenic lung non-small cell carcinomas. BrJ Cancer 2002; 86(2): 244-9.
61. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymaltransitions in development and disease. Cell 2009;139(5): 871-90.
62. Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymaltransition to facilitate tumor metastasis. Cancer Biol Ther 2004;3(11): 1058-9.
63. Tellez CS, Juri DE, Do K, et al. EMT and stem cell-like propertiesassociated with miR-205 and miR-200 epigenetic silencing areearly manifestations during carcinogen-induced transformation ofhuman lung epithelial cells. Cancer Res 2011; 71(8): 3087-97.
64. Taube JH, Herschkowitz JI, Komurov K, et al. Core epithelial-tomesenchymaltransition interactome gene-expression signature isassociated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010; 107(35): 15449-54.
65. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymalstates: acquisition of malignant and stem cell traits. NatRev Cancer 2009; 9(4): 265-73.
66. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-tomesenchymaltransition in cancer progression. Br J Cancer 2008;99(9): 1375-9.
67. Romano LA, Runyan RB. Slug is an essential target of TGFbeta2signaling in the developing chicken heart. Dev Biol 2000; 223(1):91-102.
68. Armstrong EJ, Bischoff J. Heart valve development: endothelialcell signaling and differentiation. Circ Res 2004; 95(5): 459-70.
69. Hertig A, Gangadhar T, Kalluri R. Renal studies provide an insightinto cardiac extracellular matrix remodeling during health and disease. J Mol Cell Cardiol 2010; 48(3): 497-503.
70. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discoveryof endothelial to mesenchymal transition as a source for carcinomaassociatedfibroblasts. Cancer Res 2007; 67(21): 10123-8.
71. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoieticbone marrow progenitors initiate the pre-metastaticniche. Nature 2005; 438(7069): 820-7.
72. Timmerman LA, Grego-Bessa J, Raya A, et al. Notch promotesepithelial-mesenchymal transition during cardiac development andoncogenic transformation. Genes Dev 2004; 18(1): 99-115.
73. Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E, VonderhaarBK. Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. BreastCancer Res 2009; 11(6): R82.
74. Quintana E, Shackleton M, Foster HR, et al. Phenotypic heterogeneityamong tumorigenic melanoma cells from patients that is reversibleand not hierarchically organized. Cancer Cell 2010; 18(5):510-23.
75. Postovit LM, Margaryan NV, Seftor EA, Hendrix MJ. Role ofnodal signaling and the microenvironment underlying melanomaplasticity. Pigment Cell Melanoma Res 2008; 21(3): 348-57.
76. Lee CC, Jan HJ, Lai JH, et al. Nodal promotes growth and invasionin human gliomas. Oncogene 2010; 29(21): 3110-23.
77. Theriault BL, Shepherd TG, Mujoomdar ML, Nachtigal MW. BMP4 induces EMT and Rho GTPase activation in human ovariancancer cells. Carcinogenesis 2007; 28(6): 1153-62.
78. Williams SE, Beronja S, Pasolli HA, Fuchs E. Asymmetric celldivisions promote Notch-dependent epidermal differentiation. Nature2011; 470(7334): 353-8.
79. Korswagen HC. Canonical and non-canonical Wnt signaling pathwaysin Caenorhabditis elegans: variations on a common signalingtheme. Bioessays 2002; 24(9): 801-10.
80. Krebs LT, Iwai N, Nonaka S, et al. Notch signaling regulates leftrightasymmetry determination by inducing Nodal expression. Genes Dev 2003; 17(10): 1207-12.
81. Strizzi L, Hardy KM, Seftor EA, et al. Development and cancer: atthe crossroads of Nodal and Notch signaling. Cancer Res 2009;69(18): 7131-4.
82. Strizzi L, Postovit LM, Margaryan NV, et al. Emerging roles ofnodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis 2008; 29: 91-103.
83. Minchiotti G, Parisi S, Liguori G, et al. Membrane-anchorage ofCripto protein by glycosylphosphatidylinositol and its distributionduring early mouse development. Mech Dev 2000; 90(2): 133-42.
84. Constam DB. Riding shotgun: a dual role for the epidermal growthfactor-Cripto/FRL-1/Cryptic protein Cripto in Nodal trafficking. Traffic 2009; 10(7): 783-91.
85. Blanchet MH, Le Good JA, Oorschot V, et al. Cripto localizesNodal at the limiting membrane of early endosomes. Sci Signal2008; 1(45): ra13.
86. Watanabe K, Hamada S, Bianco C, et al. Requirement of glycosylphosphatidylinositolanchor of Cripto-1 for trans activity as aNodal co-receptor. J Biol Chem 2007; 282(49): 35772-86.
87. Yan YT, Liu JJ, Luo Y, et al. Dual roles of Cripto as a ligand andcoreceptor in the nodal signaling pathway. Mol Cell Biol 2002;22(13): 4439-49.
88. Bianco C, Adkins HB, Wechselberger C, et al. Cripto-1 activatesnodal-and ALK4-dependent and-independent signaling pathwaysin mammary epithelial Cells. Mol Cell Biol 2002; 22(8): 2586-97.
89. Reissmann E, Jornvall H, Blokzijl A, et al. The orphan receptorALK7 and the Activin receptor ALK4 mediate signaling by Nodalproteins during vertebrate development. Genes Dev 2001; 15(15):2010-22.
90. Constam DB. Running the gauntlet: an overview of the modalitiesof travel employed by the putative morphogen Nodal. Curr OpinGenet Dev 2009; 19(4): 302-7.
91. Tabibzadeh S, Hemmati-Brivanlou A. Lefty at the crossroads of"stemness" and differentiative events. Stem Cells 2006; 24(9):1998-2006.
92. Saijoh Y, Oki S, Tanaka C, et al. Two nodal-responsive enhancerscontrol left-right asymmetric expression of Nodal. Dev Dyn 2005;232(4): 1031-6.
93. Norris DP, Robertson EJ. Asymmetric and node-specific nodalexpression patterns are controlled by two distinct cis-acting regulatoryelements. Genes Dev 1999; 13(12): 1575-88.
94. Raya A, Kawakami Y, Rodriguez-Esteban C, et al. Notch activityinduces Nodal expression and mediates the establishment of leftrightasymmetry in vertebrate embryos. Genes Dev 2003; 17(10):1213-8.
95. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Targeting Nodalin malignant melanoma cells. Expert Opin Ther Targets 2007;11(4): 497-505.
96. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, KulesaPM, Postovit LM. Reprogramming metastatic tumour cells withembryonic microenvironments. Nat Rev Cancer 2007; 7(4): 246-55.
97. Hardy KM, Kirschmann DA, Seftor EA, et al. Regulation of theembryonic morphogen Nodal by Notch4 facilitates manifestation ofthe aggressive melanoma phenotype. Cancer Res 2010; 70(24):10340-50.
98. Choi WY, Giraldez AJ, Schier AF. Target protectors reveal dampeningand balancing of Nodal agonist and antagonist by miR-430. Science 2007; 318(5848): 271-4.
99. Beck S, Le Good JA, Guzman M, et al. Extraembryonic proteasesregulate Nodal signalling during gastrulation. Nat Cell Biol 2002;4(12): 981-5.
100. Le Good JA, Joubin K, Giraldez AJ, et al. Nodal stability determinessignaling range. Curr Biol 2005; 15(1): 31-6.
101. Blanchet MH, Le Good JA, Mesnard D, et al. Cripto recruits Furinand PACE4 and controls Nodal trafficking during proteolyticmaturation. EMBO J 2008; 27(19): 2580-91.
102. Glebov OO, Bright NA, Nichols BJ. Flotillin-1 defines a clathrinindependentendocytic pathway in mammalian cells. Nat Cell Biol2006; 8(1): 46-54.
103. Payne CK, Jones SA, Chen C, Zhuang X. Internalization and traffickingof cell surface proteoglycans and proteoglycan-bindingligands. Traffic 2007; 8(4): 389-401.
104. Frick M, Bright NA, Riento K, Bray A, Merrified C, Nichols BJ. Coassembly of flotillins induces formation of membrane microdomains, membrane curvature, and vesicle budding. Curr Biol 2007;17(13): 1151-6.
105. Yeo C, Whitman M. Nodal signals to Smads through Criptodependentand Cripto-independent mechanisms. Mol Cell 2001;7(5): 949-57.
106. Ang SL, Constam DB. A gene network establishing polarity in theearly mouse embryo. Semin Cell Dev Biol 2004; 15(5): 555-61.
107. Zhou X, Sasaki H, Lowe L, Hogan BL, Kuehn MR. Nodal is anovel TGF-beta-like gene expressed in the mouse node during gastrulation. Nature 1993; 361(6412): 543-7.
108. Collignon J, Varlet I, Robertson EJ. Relationship between asymmetricnodal expression and the direction of embryonic turning. Nature 1996; 381(6578): 155-8.
109. Smith WC, McKendry R, Ribisi S Jr, Harland RM. A nodal-relatedgene defines a physical and functional domain within the Spemannorganizer. Cell 1995; 82(1): 37-46.
110. Shiratori H, Hamada H. The left-right axis in the mouse: fromorigin to morphology. Development 2006; 133(11): 2095-104.
111. Vallier L, Reynolds D, Pedersen RA. Nodal inhibits differentiationof human embryonic stem cells along the neuroectodermal defaultpathway. Dev Biol 2004; 275(2): 403-21.
112. James D, Levine AJ, Besser D, Hemmati-Brivanlou A. TGFbeta/activin/nodal signaling is necessary for the maintenanceof pluripotency in human embryonic stem cells. Development2005; 132(6): 1273-82.
113. Vallier L, Mendjan S, Brown S, et al. Activin/Nodal signallingmaintains pluripotency by controlling Nanog expression. Development2009; 136(8): 1339-49.
114. Smith JR, Vallier L, Lupo G, Alexander M, Harris WA, PedersenRA. Inhibition of Activin/Nodal signaling promotes specificationof human embryonic stem cells into neuroectoderm. Dev Biol2008; 313(1): 107-17.
115. Patani R, Compston A, Puddifoot CA, et al. Activin/Nodal inhibitionalone accelerates highly efficient neural conversion from humanembryonic stem cells and imposes a caudal positional identity. PLoS One 2009; 4(10): e7327.
116. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. A threedimensionalmodel to study the epigenetic effects induced by themicroenvironment of human embryonic stem cells. Stem Cells2006; 24(3): 501-5.
117. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, et al. Reprogrammingmetastatic melanoma cells to assume a neural crest cell-likephenotype in an embryonic microenvironment. Proc Natl Acad SciUSA 2006; 103(10): 3752-7.
118. Strizzi L, Postovit LM, Margaryan NV, et al. Nodal as a biomarkerfor melanoma progression and a new therapeutic target for clinicalintervention. Expert Rev Dermatol 2009; 4(1): 67-78.
119. Adkins HB, Bianco C, Schiffer SG, et al. Antibody blockade of theCripto CFC domain suppresses tumor cell growth in vivo. J ClinInvest 2003; 112(4): 575-87.
120. Vo BT, Khan SA. Expression of nodal and nodal receptors in prostatestem cells and prostate cancer cells: autocrine effects on cellproliferation and migration. Prostate 2011; 71(10): 1084-96.
121. Papageorgiou I, Nicholls PK, Wang F, et al. Expression of nodalsignalling components in cycling human endometrium and in endometrialcancer. Reprod Biol Endocrinol 2009; 7: 122.
122. Xu G, Zhong Y, Munir S, Yang BB, Tsang BK, Peng C. Nodalinduces apoptosis and inhibits proliferation in human epithelialovarian cancer cells via activin receptor-like kinase 7. J Clin EndocrinolMetab 2004; 89(11): 5523-34.
123. Munir S, Xu G, Wu Y, Yang B, Lala PK, Peng C. Nodal and ALK7inhibit proliferation and induce apoptosis in human trophoblastcells. J Biol Chem 2004; 279(30): 31277-86.
124. Hoffmann FM. TGF-beta family factors in Drosophila morphogenesis. Mol Reprod Dev 1992; 32(2): 173-8.
125. Soderberg SS, Karlsson G, Karlsson S. Complex and context dependentregulation of hematopoiesis by TGF-beta superfamily signaling. Ann N Y Acad Sci 2009; 1176: 55-69.
126. Tian M, Schiemann WP. The TGF-beta paradox in human cancer:an update. Future Oncol 2009; 5(2): 259-71.
127. Bachman KE, Park BH. Duel nature of TGF-beta signaling: tumorsuppressor vs. tumor promoter. Curr Opin Oncol 2005; 17(1): 49-54.
128. Nishita M, Hashimoto MK, Ogata S, et al. Interaction between Wntand TGF-beta signalling pathways during formation of Spemann'sorganizer. Nature 2000; 403(6771): 781-5.
129. Meno C, Saijoh Y, Fujii H, et al. Left-right asymmetric expressionof the TGF beta-family member lefty in mouse embryos. Nature1996; 381(6578): 151-5.
130. Lai EC. Notch signaling: control of cell communication and cellfate. Development 2004; 131(5): 965-73.
131. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006; 7(9): 678-89.
132. Nichols JT, Miyamoto A, Olsen SL, D'Souza B, Yao C, WeinmasterG. DSL ligand endocytosis physically dissociates Notch1 heterodimersbefore activating proteolysis can occur. J Cell Biol 2007;176(4): 445-58.
133. Fortini ME. Gamma-secretase-mediated proteolysis in cell-surfacereceptorsignalling. Nat Rev Mol Cell Biol 2002; 3(9): 673-84.
134. Mumm JS, Kopan R. Notch signaling: from the outside in. DevBiol 2000; 228(2): 151-65.
135. Nam Y, Sliz P, Song L, Aster JC, Blacklow SC. Structural basis forcooperativity in recruitment of MAML coactivators to Notch transcriptioncomplexes. Cell 2006; 124(5): 973-83.
136. Miele L. Notch signaling. Clin Cancer Res 2006; 12(4): 1074-9.
137. Iso T, Kedes L, Hamamori Y. HES and HERP families: multipleeffectors of the Notch signaling pathway. J Cell Physiol 2003;194(3): 237-55.
138. Lewis J. Neurogenic genes and vertebrate neurogenesis. Curr OpinNeurobiol 1996; 6(1): 3-10.
139. Lewis J. Notch signalling and the control of cell fate choices invertebrates. Semin Cell Dev Biol 1998; 9(6): 583-9.
140. Chitnis A, Henrique D, Lewis J, Ish-Horowicz D, Kintner C. Primaryneurogenesis in Xenopus embryos regulated by a homologueof the Drosophila neurogenic gene Delta. Nature 1995; 375(6534):761-6.
141. Henrique D, Hirsinger E, Adam J, et al. Maintenance of neuroepithelialprogenitor cells by Delta-Notch signalling in the embryonicchick retina. Curr Biol 1997; 7(9): 661-70.
142. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene ortumour suppressor? Nat Rev Cancer 2003; 3(10): 756-67.
143. Kimble J, Simpson P. The LIN-12/Notch signaling pathway and itsregulation. Annu Rev Cell Dev Biol 1997; 13: 333-61.
144. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science 1995; 268(5208): 225-32.
145. Pear WS, Radtke F. Notch signaling in lymphopoiesis. Semin Immunol2003; 15(2): 69-79.
146. Milner LA, Bigas A, Kopan R, Brashem-Stein C, Bernstein ID, Martin DI. Inhibition of granulocytic differentiation by mNotch1. Proc Natl Acad Sci USA 1996; 93(23): 13014-9.
147. Milner LA, Bigas A. Notch as a mediator of cell fate determinationin hematopoiesis: evidence and speculation. Blood 1999; 93(8):2431-48.
148. Yan XQ, Sarmiento U, Sun Y, et al. A novel Notch ligand, Dll4, induces T-cell leukemia/lymphoma when overexpressed in mice byretroviral-mediated gene transfer. Blood 2001; 98(13): 3793-9.
149. Girard L, Hanna Z, Beaulieu N, et al. Frequent provirus insertionalmutagenesis of Notch1 in thymomas of MMTVD/myc transgenicmice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev 1996; 10(15): 1930-44.
150. Rohn JL, Lauring AS, Linenberger ML, Overbaugh J. Transductionof Notch2 in feline leukemia virus-induced thymic lymphoma. JVirol 1996; 70(11): 8071-80.
151. Weng AP, Nam Y, Wolfe MS, et al. Growth suppression of pre-Tacute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003; 23(2): 655-64.
152. Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signalingmaintains the neoplastic phenotype in human Ras-transformedcells. Nat Med 2002; 8(9): 979-86.
153. Reedijk M, Odorcic S, Chang L, et al. High-level coexpression ofJAG1 and NOTCH1 is observed in human breast cancer and is associatedwith poor overall survival. Cancer Res 2005; 65(18):8530-7.
154. Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression isassociated with prostate cancer metastasis and recurrence. CancerRes 2004; 64(19): 6854-7.
155. Bismar TA, Demichelis F, Riva A, et al. Defining aggressive prostatecancer using a 12-gene model. Neoplasia 2006; 8(1): 59-68.
156. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notchsignaling in human breast cancer. Cancer Res 2006; 66(3): 1517-25.
157. Balint K, Xiao M, Pinnix CC, et al. Activation of Notch1 signalingis required for beta-catenin-mediated human primary melanomaprogression. J Clin Invest 2005; 115(11): 3166-76.
158. Hoek K, Rimm DL, Williams KR, et al. Expression profiling revealsnovel pathways in the transformation of melanocytes tomelanomas. Cancer Res 2004; 64(15): 5270-82.
159. Liu ZJ, Xiao M, Balint K, et al. Notch1 signaling promotes primarymelanoma progression by activating mitogen-activated proteinkinase/phosphatidylinositol 3-kinase-Akt pathways and upregulatingN-cadherin expression. Cancer Res 2006; 66(8): 4182-90.
160. O'Neill CF, Urs S, Cinelli C, et al. Notch2 signaling induces apoptosisand inhibits human MDA-MB-231 xenograft growth. Am JPathol 2007; 171(3): 1023-36.
161. Rangarajan A, Talora C, Okuyama R, et al. Notch signaling is adirect determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001; 20(13): 3427-36.
162. Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastomagene product. Science 1989; 243(4893): 934-7.
163. Munger K, Basile JR, Duensing S, et al. Biological activities andmolecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001; 20(54): 7888-98.
164. Helt AM, Funk JO, Galloway DA. Inactivation of both the retinoblastomatumor suppressor and p21 by the human papillomavirustype 16 E7 oncoprotein is necessary to inhibit cell cycle arrest inhuman epithelial cells. J Virol 2002; 76(20): 10559-68.
165. Westbrook TF, Nguyen DX, Thrash BR, McCance DJ. E7 abolishesraf-induced arrest via mislocalization of p21(Cip1). Mol CellBiol 2002; 22(20): 7041-52.
166. Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C. Theemerging role of Wnt signaling in the pathogenesis of acute myeloidleukemia. Leukemia 2007; 21(8): 1638-47.
167. Kawano Y, Kypta R. Secreted antagonists of the Wnt signallingpathway. J Cell Sci 2003; 116(Pt 13): 2627-34.
168. Sumi T, Tsuneyoshi N, Nakatsuji N, Suemori H. Defining earlylineage specification of human embryonic stem cells by the orchestratedbalance of canonical Wnt/beta-catenin, Activin/Nodal andBMP signaling. Development 2008; 135(17): 2969-79.
169. Tam PP, Loebel DA. Gene function in mouse embryogenesis: getset for gastrulation. Nat Rev Genet 2007; 8(5): 368-81.
170. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and betacateninsignalling: diseases and therapies. Nat Rev Genet 2004;5(9): 691-701.
171. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stemcells through activation of Wnt signaling by a pharmacologicalGSK-3-specific inhibitor. Nat Med 2004; 10(1): 55-63.
172. Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of theWnt pathway in the pathology of human cancers. Pathology 2004;36(2): 120-8.
173. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as atarget of the APC pathway. Science 1998; 281(5382): 1509-12.
174. Hart MJ, de los SR, Albert IN, Rubinfeld B, Polakis P. Downregulationof beta-catenin by human Axin and its association with theAPC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol1998; 8(10): 573-81.
175. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms acomplex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998;17(5): 1371-84.
176. Verani R, Cappuccio I, Spinsanti P, et al. Expression of the Wntinhibitor Dickkopf-1 is required for the induction of neural markersin mouse embryonic stem cells differentiating in response to retinoicacid. J Neurochem 2007; 100(1): 242-50.
177. Bradley L, Sun B, Collins-Racie L, LaVallie E, McCoy J, Sive H. Different activities of the frizzled-related proteins frzb2 and sizzled2during Xenopus anteroposterior patterning. Dev Biol 2000;227(1): 118-32.
178. Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, HowePH. Regulation of the Wnt signaling pathway by disabled-2(Dab2). EMBO J 2003; 22(12): 3084-94.
179. Cheyette BN, Waxman JS, Miller JR, et al. Dapper, a Dishevelledassociatedantagonist of beta-catenin and JNK signaling, is requiredfor notochord formation. Dev Cell 2002; 2(4): 449-61.
180. Morin PJ. beta-catenin signaling and cancer. Bioessays 1999;21(12): 1021-30.
181. Takemaru K, Yamaguchi S, Lee YS, Zhang Y, Carthew RW, MoonRT. Chibby, a nuclear beta-catenin-associated antagonist of theWnt/Wingless pathway. Nature 2003; 422(6934): 905-9.
182. Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, KemlerR. Lack of beta-catenin affects mouse development at gastrulation. Development 1995; 121(11): 3529-37.
183. Austin TW, Solar GP, Ziegler FC, Liem L, Matthews W. A role forthe Wnt gene family in hematopoiesis: expansion of multilineageprogenitor cells. Blood 1997; 89(10): 3624-35.
184. Brandon C, Eisenberg LM, Eisenberg CA. WNT signaling modulatesthe diversification of hematopoietic cells. Blood 2000; 96(13):4132-41.
185. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling inself-renewal of haematopoietic stem cells. Nature 2003; 423(6938):409-14.
186. Ko KH, Holmes T, Palladinetti P, et al. GSK-3beta inhibition promotesengraftment of ex vivo-expanded hematopoietic stem cellsand modulates gene expression. Stem Cells 2011; 29(1): 108-18.
187. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127(3): 469-80.
188. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature2005; 434(7035): 843-50.
189. Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stemcellcompartments in the small intestine of mice lacking Tcf-4. NatGenet 1998; 19(4): 379-83.
190. Kim KA, Kakitani M, Zhao J, et al. Mitogenic influence of humanR-spondin1 on the intestinal epithelium. Science 2005; 309(5738):1256-9.
191. Lowry WE, Blanpain C, Nowak JA, Guasch G, Lewis L, Fuchs E. Defining the impact of beta-catenin/Tcf transactivation on epithelialstem cells. Genes Dev 2005; 19(13): 1596-611.
192. Liu Y. New Insights into Epithelial-Mesenchymal Transition inKidney Fibrosis. J Am Soc Nephrol 2009.
193. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14(15):1837-51.
194. Kiesslich T, Alinger B, Wolkersdorfer GW, Ocker M, Neureiter D, Berr F. Active Wnt signalling is associated with low differentiationand high proliferation in human biliary tract cancer in vitro and invivo and is sensitive to pharmacological inhibition. Int J Oncol2010; 36(1): 49-58.
195. Jiang YG, Luo Y, He DL, et al. Role of Wnt/beta-catenin signalingpathway in epithelial-mesenchymal transition of human prostatecancer induced by hypoxia-inducible factor-1alpha. Int J Urol2007; 14(11): 1034-9.
196. Kinzler KW, Vogelstein B. Lessons from hereditary colorectalcancer. Cell 1996; 87(2): 159-70.
197. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptionalactivation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997; 275(5307): 1784-7.
198. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275(5307): 1787-90.
199. Liu W, Dong X, Mai M, et al. Mutations in AXIN2 cause colorectalcancer with defective mismatch repair by activating betacatenin/TCF signalling. Nat Genet 2000; 26(2): 146-7.
200. Takeda H, Lyle S, Lazar AJ, Zouboulis CC, Smyth I, Watt FM. Human sebaceous tumors harbor inactivating mutations in LEF1. Nat Med 2006; 12(4): 395-7.
201. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenicmice for studying the genetic basis of breast cancer. Oncogene2000; 19(8): 1002-9.
202. Li Y, Welm B, Podsypanina K, et al. Evidence that transgenesencoding components of the Wnt signaling pathway preferentiallyinduce mammary cancers from progenitor cells. Proc Natl Acad SciUSA 2003; 100(26): 15853-8.
203. Liu BY, McDermott SP, Khwaja SS, Alexander CM. The transformingactivity of Wnt effectors correlates with their ability to inducethe accumulation of mammary progenitor cells. Proc NatlAcad Sci USA 2004; 101(12): 4158-63.
204. Takeuchi JK, Lickert H, Bisgrove BW, et al. Baf60c is a nuclearNotch signaling component required for the establishment of leftrightasymmetry. Proc Natl Acad Sci USA 2007; 104(3): 846-51.
205. Watanabe K, Nagaoka T, Lee JM, et al. Enhancement of Notchreceptor maturation and signaling sensitivity by Cripto-1. J CellBiol 2009; 187(3): 343-53.
206. Yamaguchi TP, Takada S, Yoshikawa Y, Wu N, McMahon AP. T(Brachyury) is a direct target of Wnt3a during paraxial mesodermspecification. Genes Dev 1999; 13(24): 3185-90.
207. Zhang L, Zhou H, Su Y, Sun Z, et al. Zebrafish Dpr2 inhibitsmesoderm induction by promoting degradation of nodal receptors. Science 2004; 306(5693): 114-7.
208. Piccolo S, Agius E, Leyns L, et al. The head inducer Cerberus is amultifunctional antagonist of Nodal, BMP and Wnt signals. Nature1999; 397(6721): 707-10.
209. Tian T, Meng AM. Nodal signals pattern vertebrate embryos. CellMol Life Sci 2006; 63(6): 672-85.
210. Branford WW, Yost HJ. Lefty-dependent inhibition of Nodal-andWnt-responsive organizer gene expression is essential for normalgastrulation. Curr Biol 2002; 12(24): 2136-41.
211. Meno C, Ito Y, Saijoh Y, et al. Two closely-related left-rightasymmetrically expressed genes, lefty-1 and lefty-2: their distinctexpression domains, chromosomal linkage and direct neuralizingactivity in Xenopus embryos. Genes Cells 1997; 2(8): 513-24.
212. Agathon A, Thisse C, Thisse B. The molecular nature of the zebrafishtail organizer. Nature 2003; 424(6947): 448-52.
213. Nathan AT, Singer M. The oxygen trail: tissue oxygenation. BrMed Bull 1999; 55(1): 96-108.
214. Birol G, Wang S, Budzynski E, Wangsa-Wirawan ND, LinsenmeierRA. Oxygen distribution and consumption in the macaqueretina. Am J Physiol Heart Circ Physiol 2007; 293(3): H1696-H1704.
215. Wenger RH. Cellular adaptation to hypoxia: O2-sensing proteinhydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002; 16(10): 1151-62.
216. Hochachka PW, Lutz PL. Mechanism, origin, and evolution ofanoxia tolerance in animals. Comp Biochem Physiol B BiochemMol Biol 2001; 130(4): 435-59.
217. Hochachka PW, Buck LT, Doll CJ, Land SC. Unifying theory ofhypoxia tolerance: molecular/metabolic defense and rescue mechanismsfor surviving oxygen lack. Proc Natl Acad Sci USA 1996;93(18): 9493-8.
218. Wenger RH. Mammalian oxygen sensing, signalling and generegulation. J Exp Biol 2000; 203(Pt 8): 1253-63.
219. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolismin cancer cells by inducing over-expression of specificglycolytic isoforms. Mini Rev Med Chem 2009; 9(9): 1084-101.
220. Harris AL. Hypoxia--a key regulatory factor in tumour growth. NatRev Cancer 2002; 2(1): 38-47.
221. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer2003; 3(10): 721-32.
222. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev 2007;26(2): 223-4.
223. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedicalrelevance. J Biol Chem 2003; 278(22): 19575-8.
224. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. SciSTKE 2007; 2007(407): cm8.
225. Coleman ML, Ratcliffe PJ. Oxygen sensing and hypoxia-inducedresponses. Essays Biochem 2007; 43: 1-15.
226. Brahimi-Horn C, Pouyssegur J. The role of the hypoxia-induciblefactor in tumor metabolism growth and invasion. Bull Cancer 2006;93(8): E73-E80.
227. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, andcancer. Cell 2007; 129(3): 465-72.
228. Raval RR, Lau KW, Tran MG, et al. Contrasting properties ofhypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25(13): 5675-86.
229. Wiesener MS, Jurgensen JS, Rosenberger C, et al. Widespreadhypoxia-inducible expression of HIF-2alpha in distinct cell populationsof different organs. FASEB J 2003; 17(2): 271-3.
230. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of humanplacental development by oxygen tension. Science 1997;277(5332): 1669-72.
231. Jauniaux E, Watson A, Burton G. Evaluation of respiratory gasesand acid-base gradients in human fetal fluids and uteroplacental tissuebetween 7 and 16 weeks' gestation. Am J Obstet Gynecol 2001;184(5): 998-1003.
232. Ezashi T, Das P, Roberts RM. Low O2 tensions and the preventionof differentiation of hES cells. Proc Natl Acad Sci USA 2005;102(13): 4783-8.
233. Cipolleschi MG, Dello SP, Olivotto M. The role of hypoxia in themaintenance of hematopoietic stem cells. Blood 1993; 82(7): 2031-7.
234. Danet GH, Pan Y, Luongo JL, Bonnet DA, Simon MC. Expansionof human SCID-repopulating cells under hypoxic conditions. J ClinInvest 2003; 112(1): 126-35.
235. Morrison SJ, Csete M, Groves AK, Melega W, Wold B, Anderson DJ. Culture in reduced levels of oxygen promotes clonogenic sympathoadrenaldifferentiation by isolated neural crest stem cells. JNeurosci 2000; 20(19): 7370-6.
236. Studer L, Csete M, Lee SH, et al. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in loweredoxygen. J Neurosci 2000; 20(19): 7377-83.
237. Kingdom JC, Kaufmann P. Oxygen and placental vascular development. Adv Exp Med Biol 1999; 474: 259-75.
238. Patel J, Landers K, Mortimer RH, Richard K. Regulation of hypoxiainducible factors (HIF) in hypoxia and normoxia during placentaldevelopment. Placenta 2010; 31(11): 951-7.
239. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acutemyocardial ischemia and infarction. N Engl J Med 2000; 342(9):626-33.
240. Walgenbach KJ, Gratas C, Shestak KC, Becker D. Ischaemiainducedexpression of bFGF in normal skeletal muscle: a potentialparacrine mechanism for mediating angiogenesis in ischaemicskeletal muscle. Nat Med 1995; 1(5): 453-9.
241. Simon MC, Keith B. The role of oxygen availability in embryonicdevelopment and stem cell function. Nat Rev Mol Cell Biol 2008;9(4): 285-96.
242. Thomlinson RH, Gray LH. The histological structure of somehuman lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9(4): 539-49.
243. Franko AJ, Sutherland RM. Rate of death of hypoxic cells in multicellspheroids. Radiat Res 1978; 76(3): 561-72.
244. Durand RE, Raleigh JA. Identification of nonproliferating butviable hypoxic tumor cells in vivo. Cancer Res 1998; 58(16): 3547-50.
245. Bennewith KL, Durand RE. Quantifying transient hypoxia in humantumor xenografts by flow cytometry. Cancer Res 2004;64(17): 6183-9.
246. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW, Dewhirst MW. Direct demonstration of instabilities in oxygen concentrationswithin the extravascular compartment of an experimental tumor. Cancer Res 2006; 66(4): 2219-23.
247. 2in irradiated human melanoma xenografts. Radiat Res 2006;165(1): 16-25.
248. Holmquist L, Jogi A, Pahlman S. Phenotypic persistence afterreoxygenation of hypoxic neuroblastoma cells. Int J Cancer 2005;116(2): 218-25.
249. Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009; 19(2): 106-11.
250. Soeda A, Park M, Lee D, et al. Hypoxia promotes expansion of theCD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28(45): 3949-59.
251. Helczynska K, Kronblad A, Jogi A, et al. Hypoxia promotes adedifferentiated phenotype in ductal breast carcinoma in situ. CancerRes 2003; 63(7): 1441-4.
252. Pietras A, Gisselsson D, Ora I, et al. High levels of HIF-2alphahighlight an immature neural crest-like neuroblastoma cell cohortlocated in a perivascular niche. J Pathol 2008; 214(4): 482-8.
253. Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonicstem cell markers in cancer cells. Cancer Res 2011; 71(13): 4640-52.
254. Covello KL, Kehler J, Yu H, et al. HIF-2alpha regulates Oct-4:effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006; 20(5): 557-70.
255. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: evidence in support ofthe stem cell theory of carcinogenesis. Carcinogenesis 2005; 26(2):495-502.
256. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dosedependentoncogenic fate determinant. Cancer Cell 2003; 4(5):361-70.
257. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008;22(20): 2755-66.
258. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteractingMyc. EMBO J 2004; 23(9): 1949-56.
259. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alphapromotes hypoxic cell proliferation by enhancing c-myc transcriptionalactivity. Cancer Cell 2007; 11(4): 335-47.
260. Takahashi K, Yamanaka S. Induction of pluripotent stem cells frommouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-76.
261. Maherali N, Sridharan R, Xie W, et al. Directly reprogrammedfibroblasts show global epigenetic remodeling and widespread tissuecontribution. Cell Stem Cell 2007; 1(1): 55-70.
262. Gustafsson MV, Zheng X, Pereira T, et al. Hypoxia requires notchsignaling to maintain the undifferentiated cell state. Dev Cell 2005;9(5): 617-28.
263. Androutsellis-Theotokis A, Leker RR, Soldner F, et al. Notchsignalling regulates stem cell numbers in vitro and in vivo. Nature2006; 442(7104): 823-6.
264. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. Notch signals control the fate of immature progenitorcells in the intestine. Nature 2005; 435(7044): 964-8.
265. van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma-secretaseinhibition turns proliferative cells in intestinal crypts and adenomasinto goblet cells. Nature 2005; 435(7044): 959-63.
266. Kumano K, Chiba S, Kunisato A, et al. Notch1 but not Notch2 isessential for generating hematopoietic stem cells from endothelialcells. Immunity 2003; 18(5): 699-711.
267. Quail DF, Taylor M, Walsh L, et al. Low oxygen levels induce theexpression of the embryonic morphogen Nodal. Mol Biol Cell2011; 22(24): 4809-21.
268. Kaidi A, Williams AC, Paraskeva C. Interaction between betacateninand HIF-1 promotes cellular adaptation to hypoxia. NatCell Biol 2007; 9(2): 210-7.
269. Choi H, Chun YS, Kim TY, Park JW. HIF-2alpha enhances betacatenin/TCF-driven transcription by interacting with beta-catenin. Cancer Res 2010; 70(24): 10101-11.
270. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulationof the multidrug resistance (MDR1) gene. Cancer Res 2002;62(12): 3387-94.
271. Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cellmarker Bcrp/ABCG2 enhances hypoxic cell survival through interactionswith heme. J Biol Chem 2004; 279(23): 24218-25.
272. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. Hypoxiainduciblefactor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 2004; 24(13): 6076-83.
273. McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. Transforming growth factor beta1 induces hypoxia-induciblefactor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 2006; 281(34): 24171-81.
274. Onishi H, Kai M, Odate S, et al. Hypoxia activates the hedgehogsignaling pathway in a ligand-independent manner by upregulationof Smo transcription in pancreatic cancer. Cancer Sci 2011; 102(6):1144-50.